Thyroid Cancer Survival Rates: What the Numbers Mean
If you or someone you love has just been given a thyroid cancer diagnosis, you have probably already searched for survival statistics. A relative survival rate compares a group of people who have a certain cancer to a similar group of people in the general population who do not have that cancer. If a 5 year relative survival rate (the percent of people alive 5 years after diagnosis, compared to people without the cancer) for a certain type and stage of thyroid cancer is 97%, that means people with that diagnosis are, on average, about 97% as likely as people without it to be alive 5 years later. These numbers come from large registries, most often the Surveillance, Epidemiology, and End Results (SEER) program run by the National Cancer Institute, which tracks outcomes for tens of thousands of people over many years.
Here is what a survival rate cannot do. It cannot predict what will happen to you. It is built from data on people who were diagnosed and treated years ago, often a decade or more before today, so people diagnosed now may do better because treatment keeps improving. It also blends together people with different ages, tumor genetics, and overall health into a single number. Your own outlook depends on details specific to your case that a statistic simply cannot capture. Your doctor is the only person who can look at your full picture and help you understand what these numbers might mean for you.
It is also worth naming something that many patients feel but rarely hear said out loud. Differentiated thyroid cancer, the most common form, often comes with very good survival statistics, and that is genuinely good news. But good statistics do not erase what you are living through. A cancer diagnosis is still a cancer diagnosis. Thyroid surgery is still major surgery, often followed by a visible neck scar and questions about your voice. Lifelong medication is still a daily responsibility you did not ask for. Recovery, follow up scans, and the fear of recurrence are still real, even when the odds are in your favor.
If a friend, coworker, or even a well-meaning relative has told you that thyroid cancer is "the good cancer" or "the easy one," you are allowed to feel frustrated by that. Being told your cancer does not count as a real hardship can feel dismissive and lonely, even from people who mean well. Your experience is valid regardless of what the statistics say about your particular subtype. You can hold both truths at once: gratitude that outcomes for many thyroid cancers are often favorable, and honesty about how hard this diagnosis and its aftermath can be.
What Are the Survival Rates for Thyroid Cancer?
Most thyroid cancers are either papillary thyroid carcinoma or follicular thyroid carcinoma. Together, these are called differentiated thyroid cancer (DTC) because the cancer cells still look and behave somewhat like normal thyroid cells. DTC makes up the large majority of all thyroid cancer cases and is generally treated with surgery, sometimes followed by radioactive iodine treatment.
The American Cancer Society reports these numbers using SEER stage groups rather than the more detailed AJCC TNM staging system. SEER groups cancers into three categories:
Localized (no sign the cancer has spread outside the thyroid)
Regional (the cancer has spread to nearby structures or lymph nodes)
Distant (the cancer has spread to distant parts of the body, such as the lungs or bones).
These figures reflect people diagnosed between 2015 and 2021.
Papillary thyroid cancer, which accounts for roughly 80 to 85% of all thyroid cancer cases, has the following 5 year relative survival rates by SEER stage:
SEER Stage | 5-Year Relative Survival Rate |
|---|---|
Localized | greater than 99% |
Regional | 99% |
Distant | 71% |
All SEER stages combined | greater than 99% |
Follicular thyroid cancer, which makes up roughly 10 to 15% of thyroid cancer cases, has these 5 year relative survival rates:
SEER Stage | 5-Year Relative Survival Rate |
|---|---|
Localized | greater than 99% |
Regional | 97% |
Distant | 62% |
All SEER stages combined | 98% |
Notice that even the distant stage numbers for both papillary and follicular thyroid cancer are meaningfully better than distant stage numbers for many other cancer types. This reflects real biological differences in how these cancers tend to behave. It does not mean a distant stage diagnosis is easy news, and your care team can walk you through what your specific imaging and pathology results mean for your situation.
Survival Rates for Medullary Thyroid Cancer
Medullary thyroid cancer (MTC) works differently from papillary and follicular thyroid cancer in almost every way, including survival. MTC starts in C cells (calcitonin-producing cells), not the follicular cells that give rise to DTC. Because of this, MTC is not treated with radioactive iodine, uses different tumor markers (calcitonin and carcinoembryonic antigen, or CEA), and about one quarter of cases are hereditary, linked to RET gene mutations. Genetic testing for RET mutations is recommended for every person diagnosed with MTC, since it can affect both your own treatment and screening for family members.
The American Cancer Society reports these SEER stage-based 5-year relative survival rates for medullary thyroid cancer, based on people diagnosed between 2015 and 2021:
SEER Stage | 5-Year Relative Survival Rate |
|---|---|
Localized | greater than 99% |
Regional | 94% |
Distant | 50% |
All SEER stages combined | 93% |
Survival Rates for Anaplastic Thyroid Cancer
Anaplastic thyroid cancer (ATC) is a different, much more aggressive disease, and it deserves honesty rather than reassurance that does not fit the facts. ATC accounts for roughly 1 to 2% of thyroid cancers in the United States, but because it grows and spreads so quickly, it is treated as a medical emergency requiring urgent, coordinated care from a multidisciplinary team. Every case of ATC is classified as at least AJCC stage IV, regardless of tumor size, because of how the disease behaves.
The American Cancer Society reports these SEER stage-based 5-year relative survival rates for anaplastic thyroid cancer:
SEER Stage | 5-Year Relative Survival Rate |
|---|---|
Localized | 45% |
Regional | 14% |
Distant | 5% |
All SEER stages combined | 10% |
Older, historical data from SEER-based studies put median overall survival for ATC at around 4 to 6 months. That picture, while still sobering, is changing. A more recent analysis of patients treated with modern, multimodality care, including surgery, radiation, chemotherapy, and targeted therapy where appropriate, found a median overall survival closer to 9.5 months. The most striking recent progress has come in tumors with a BRAF V600E mutation (a specific, testable change in a gene that drives cell growth). Patients with BRAF mutant ATC who received targeted therapy with dabrafenib plus trametinib, a combination specifically approved by the FDA for this mutation, had a 1 year survival rate of 94% in that same analysis. This is real, meaningful progress, not a cure, and not something every patient with ATC will experience, since it depends on the tumor's specific mutation status and how early treatment begins. BRAF testing is a genuinely important step for anyone diagnosed with ATC, and your oncology team can explain whether targeted therapy is an option in your case.
Poorly differentiated thyroid carcinoma sits between DTC and ATC in how it behaves and is generally treated more aggressively than papillary or follicular thyroid cancer, though it is not covered here in detail. If you have been told your tumor is poorly differentiated, ask your care team how that specific finding affects your treatment plan and outlook.
What Factors Affect Thyroid Cancer Survival?
Survival statistics are grouped by stage, but stage is only one piece of the picture. Several other factors shape an individual's outlook, and understanding them can help you make sense of what your own doctors are watching closely.
Age at diagnosis: Age plays an unusually large role in differentiated thyroid cancer staging. The current AJCC staging system uses a cutoff of 55 years old. People younger than 55 with DTC are staged using only two categories (stage I or stage II) because their disease tends to behave less aggressively, even when it has spread. People 55 and older are staged using a more detailed, four-stage system, since older age at diagnosis is linked to a higher risk of recurrence and worse outcomes, independent of how far the cancer has spread.
Tumor size and extent: Larger tumors and tumors that grow through the thyroid capsule into nearby tissue tend to carry a higher risk of recurrence and are associated with lower survival rates, particularly for follicular and medullary thyroid cancer.
Lymph node and distant spread: Spread to lymph nodes in the neck has a smaller impact on outlook for differentiated thyroid cancer than it does for many other cancers, but distant spread, most often to the lungs or bones, has the biggest effect on survival across all thyroid cancer subtypes.
Completeness of surgical resection: Whether the surgeon is able to remove all visible tumor matters a great deal, especially for medullary and anaplastic thyroid cancer, where incomplete resection is linked to a meaningfully worse prognosis.
Tumor subtype and specific mutations: As covered above, papillary and follicular thyroid cancer generally carry a better prognosis than medullary or anaplastic thyroid cancer. Within each subtype, specific gene changes matter too. BRAF V600E mutations are common in papillary thyroid cancer and can be linked to more aggressive disease and a stronger response to certain targeted drugs. RAS mutations are more common in follicular thyroid cancer. RET mutations or rearrangements are central to medullary thyroid cancer and appear in a subset of papillary thyroid cancers as well. TERT promoter mutations, when present, are associated with more aggressive behavior and a higher chance the cancer will become less differentiated over time.
Response to initial treatment: How your body responds to your first round of surgery, and radioactive iodine if used, is one of the strongest predictors doctors use to estimate your ongoing risk. A good initial response is reassuring, and a less complete response simply means your team will watch more closely and may recommend additional treatment.
Living as a Thyroid Cancer Survivor
Finishing initial treatment does not mean thyroid cancer is entirely behind you. For most survivors, life afterward includes lifelong monitoring and, in most cases, lifelong medication.
Follow-up typically includes periodic neck ultrasound to look for any sign of recurrence in the thyroid bed or nearby lymph nodes. Blood tests are used alongside imaging, and which test matters depends on your subtype. For differentiated thyroid cancer, doctors track thyroglobulin (a protein made only by thyroid tissue, which should be very low or undetectable after a total thyroidectomy) along with thyroglobulin antibodies, since rising levels can be an early sign of recurrence. For medullary thyroid cancer, doctors instead track calcitonin and CEA, the tumor markers specific to that disease. These checks usually happen every few months at first, then spread out to once or twice a year if things stay stable.
If you had your thyroid removed, you will need levothyroxine, a synthetic thyroid hormone, for the rest of your life. Many thyroid cancer survivors are kept on a slightly higher dose than someone with an underactive thyroid alone would need, on purpose, to suppress TSH (thyroid-stimulating hormone) and reduce the chance the cancer will come back. This is a deliberate medical strategy, not a mistake, though it does mean your labs may look different from what you would expect with routine thyroid hormone replacement. Getting the dose right takes regular TSH monitoring and some patience, and small changes in how you take the medication, such as taking it on an empty stomach and spacing it away from calcium, iron, or certain antacids, can meaningfully affect how well it works.
The emotional side of long-term surveillance is real and deserves attention too. Many survivors describe a wave of anxiety in the days before each ultrasound or lab draw, sometimes called scan anxiety, even years after treatment ends. Neck scars fade but do not disappear, and some people notice lasting voice changes if a nerve near the thyroid was affected during surgery. None of this means something went wrong. It means you are living with the long term reality of a cancer diagnosis, which is worth acknowledging rather than minimizing. Our thyroid cancer support guide has more on coping with this stage and connecting with others who understand it, and our guide on questions to ask about thyroid cancer can help you prepare for follow up appointments.
Only your own care team, with full knowledge of your pathology, imaging, and treatment response, can give you a realistic sense of your personal outlook. Statistics are a starting point for a conversation with your doctor, not a substitute for one.